PULLMAN, WA September 29, 2023 - Hexamer Therapeutics Inc. has a powerful breakthrough technology for the rapid development of safe vaccines against COVID-19 variants and emerging infectious diseases. By combining Hexamer's proprietary vaccine platform and advance AI technology it enables the creation of vaccines that self-assemble into peptides, triggering a robust and durable immune response in patients.

"We are thrilled to receive a $4M contract from the USAMRDC to further develop our next generation vaccine platform," said Robert Bogden, CEO of Hexamer Therapeutics. "Our team has been tirelessly working on this innovative technology and we are confident it will soon revolutionize the way we respond to pandemics and emerging diseases."

The Self-Assembling Vaccine Platform carries several advantages over traditional vaccines, including low-cost and scalable manufacturing capabilities, as well as a flexible design that can be easily adapted to target specific variants and infectious agents. Additionally, the platform could be rapidly deployed in response to outbreaks and pandemics, providing a powerful tool to contain the spread of infectious diseases.

"We are excited to see the potential impact that the Self-Assembling Vaccine Platform can have on public health," said a spokesperson for the USAMRDC. "We see this funding as an investment in the future of global health security, and we look forward to working with Hexamer Therapeutics to bring this technology to the forefront of vaccine development."

Chief Scientific Officer and Co-Founder Dr. Colin Collins added “I see this investment by the USAMRDC as a validation of our unique vaccine technology for rapid and affordable pandemic responses and as a an important toward additional healthcare applications”.

The funding from the USAMRDC marks a significant milestone for Hexamer Therapeutics for the Self-Assembling Vaccine Platform. With the support of this prestigious organization, the company is poised to accelerate the development of the platform and bring it closer to commercialization.

For more information contact:
Robert Bogden
CEO and Co-Founder
Hexamer Therapeutics
Email: bogden@hexthera.com